Introduction
The PI3K pathway plays a pivotal role in cell growth, proliferation, survival and metabolism (1, 2) . Lesions in key pathway components can lead to gain-of-function, pathway hyperactivation, aberrant cell proliferation and subsequently to the promotion and maintenance of cancer. For example, the PIK3CA gene encoding the p110α catalytic subunit has been found to be amplified and frequently mutated in a variety of human cancers (3) . Furthermore, the antagonistic dual lipid/protein phosphatase PTEN is often inactivated by copy number loss, mutation or epigenetic silencing (4) . In addition, the downstream target Akt has been found amplified or mutated in human cancer (5) . Over the last years, evidence of oncogenic mutations in the gene coding for the regulatory subunit of PI3K, p85, has also been accumulating (6, 7) . Last but not least, constitutively activated receptor tyrosine kinases, such as for example amplified HER2 (breast) can cause hyper-activation of the PI3K pathway (8) .
The pharmaceutical industry heavily invested in the last decade to develop PI3K inhibitors with various profiles, such as dual mTOR/PI3K, pan-PI3K and even isoform specific PI3K inhibitors for clinical application. From this plethora of molecules (9) , efficacy and safety data from phase I clinical trials has recently become available (10) .
NVP-BKM120 (referred herein as BKM120) is a pan PI3K inhibitor which has recently entered clinical phase II for treatment of PI3K dependent cancers (11) . In mechanistic cellular systems, BKM120 inhibits all Class IA PI3K paralogs (p110α, β and δ) that are generally activated by receptor tyrosine signaling. In contrast, BKM120 does not significantly inhibit class II and IV PI3K homologs or protein kinases.
MCT-11-1021 BKM120 alters microtubule dynamics at high concentrations 5 When tested in proliferation assays across a large panel of cell lines (the Cell Line Encyclopedia, or CLE) encompassing different lineages and oncogenic addictions, BKM120
behaved differently compared to other PI3K inhibitors, at concentrations above 2 μM.
Specifically, the compound was efficacious against tumor lines that did not display PI3K addiction. Hence, despite the fact that its biochemical profile is very specific, we suspected that at concentrations 5-to 10-fold of those necessary to half-maximally modulate PI3K signaling, other properties were acquired. Here we demonstrate that BKM120, at high concentrations, can act as a microtubule destabilizer via direct tubulin binding. The consequences of these findings for the interpretation of in vitro and in vivo data are presented and discussed.
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Materials and Methods

Compounds, reagents and antibodies
The structures of the compounds used in this manuscript are shown in Figure 5B . BKM120 (Novartis), BEZ235 (Novartis) and GDC-0941 (BioDuro, Beijing, China) were prepared as 10 mM stock solutions in 100% DMSO. Working solutions were freshly prepared prior to addition to the cell media such that final DMSO concentrations were kept constant at 0.1% in both control and compound-treated cells. Nocodazole (#M1404) and poly-D lysine (#P6407)
were purchased from Sigma. MG-132 and DAPI were from Calbiochem (#474790) and Invitrogen (#D3571), respectively. The origin of the primary antibodies used were as follows:
anti-Akt-S473P (#9271), anti-Histone 3-P (#9701), anti-caspase 7 (#9491), anti-alpha-tubulin (#T6199), were from Cell Signaling Technologies. The Anti-gamma tubulin (#T6557) and FITC-labeled anti-alpha tubulin (#F2128) antibodies were from Sigma. The secondary Alexa fluor 568 conjugated anti-mouse antibody (#11031) was purchased from Invitrogen.
In vitro assays
Tubulin polymerisation assay: All assays were performed with the porcine tubulin polymerization kit from Cytoskeleton (#BK006-P), according to the manufacturers' protocol.
NMR binding studies:
Prior to studies, lyophilized purified bovine brain tubulin (Cytoskeleton, # TL238) was dissolved in 50 mM PBS (pH 7.0), without GTP and Mg 2+ to prevent polymerization. BKM210 was freshly prepared as a 20 mM stock solution in d 6 -DMSO (Armar Chemicals / # 015200.2040). The final concentration in NMR samples was 0.2 mM. The spectroscopy studies were performed on a Bruker AV-III-600 spectrometer WaterLOGSY experiments were measured in sensitive mode as described before (12). MCT-11-1021 BKM120 alters microtubule dynamics at high concentrations 8 cm dishes at the indicated inoculum. Cells were exposed either for either 1 h (for PI3K pathway markers) or 6 h (for G2/M markers), prior to lysis for Western-blotting or RPA analysis as described (14) .
Cellular Biology
Colony formation and FACS assays:
The FACS assays were performed as described (15) .
Colony formation assays were conducted by seeding 5 x 10 3 MCF7-BP of MCF7-myr-Akt cells in 6-well clusters. 16 h later, the medium was discarded and replaced with 2 mL of fresh medium containing the test items. The media was replaced every 3 days throughout the experiment. The experiment was stopped by adding 500 µl of 20% glutaraldehyde to the media. Ten minutes later the wells were washed with water and exposed to a 0.05% methylene blue solution 15 min. Wells were then washed with water and colonies photographed with a Canosan 4400F scanner. 
Gene expression analysis
mRNA extraction and microarray profiling: mRNA was extracted with the QiaShredder and RNA easy mini kit (Qiagen/ #79656 and #74104, respectively) according to the manufacturer's protocol. Synthesis of labeled cDNA, hybridization to HG-U133-plus2 arrays (Affymetrix Inc, Santa Clara, CA, USA), quality control and processing using the MAS5 algorithm was done essentially as described previously (16) . Microarray data are available at the Gene Expression Omnibus (GEO) database under the accession number GSE33643. GSEA was performed with an in-house implementation of Mootha's method using the twosample Wilcoxon rank-sum test (17, 18) using the MetaCore database by GeneGO, Inc, St.
Expression data analysis:
Joseph, MI, USA. The enrichment score was divided by the square root of the set size to adjust for the set size bias as suggested in (19) . Calculations were performed with R (20), final results were plotted with Spotfire (TIBCO Spotfire Inc, Somerville, MA, USA).
In vivo studies
Compound preparation: BKM120 was formulated in NMP/PEG300 (10/90, V/V). Solutions were freshly prepared for each day of dosing by dissolving the powder, first in NMP with sonication and then by adding the remaining volume of PEG300. 
Results
Comparison of BKM120 with another pan-PI3K inhibitor, GDC-0941, across a large panel of cell lines
We compared the sensitivity profile of BKM120 to another class I PI3K inhibitor, GDC-0941 (21, 22) in a panel of 381 cell lines from the Novartis / Broad Institute Cell Line Encyclopedia (CLE). The results are represented using the density distribution of the Amax (efficacy) and the crossing point (potency) for both compounds ( Figure 1 ). We observed a shift to the right of the density distribution of the crossing point for BKM120 indicating that the compound is generally less potent than GDC-0941, but we also noted an significant shift of the Amax density distribution for GDC-0941 indicating that BKM120 is overall more efficacious than GDC-0941. By setting thresholds of sensitivity using the median efficacy and potency of BKM120, 21 cell lines are defined as sensitive to GDC-0941 whereas 131 cell lines are sensitive to BKM120 (supplementary figure 1) . However, as GDC-0941 is more potent than BKM120 in inhibiting Akt phosphorylation and proliferation of PI3K addicted cell lines (Figures 2 and 3A) , we speculated that BKM120 carries activities beyond targeting PI3K.
BKM120 exhibits an off target activity at high concentrations which is not related to PI3K inhibition
In order to further characterize the potential off target activities of BKM120, we determined the effects on pathway inhibition and cell proliferation and viability in both PI3K (PIK3CA mutant MCF7 cell line) or non-PI3K addicted (PTEN mutant/BRAF mutant A2058 cell line) models. As expected, in MCF7 cells, both BKM120 ( To further elaborate on the hypothesis that additional properties besides PI3K inhibition were involved in the cell killing effects observed at high concentrations in non-PI3K addicted models, similar studies were performed in genetically engineered MCF7 cells over-expressing a dominant active form (MCF7-myr-Akt) of the downstream PI3K effector Akt (Sup Figure   2A ). In contrast to the MCF7 control cell pool (MCF7-BP), both BKM120 and GDC-0941 were less efficient in inhibiting the pathway, demonstrating that the exogenously expressed myr-Akt protein was by-passing PI3K dependence for its activation (Sup Figure 2B) . In proliferation assays ( Figure 2B ), MCF7-myr-Akt cells were found to be less sensitive than MCF7-BP cells to GDC-0941 (GI 50 = 270 ± 18 and 29 ± 10 nM, respectively) and BKM120 (GI 50 = 299 ± 68 and 76 ± 17 nM, respectively) resulting in a 9-and 4-fold shift in GI 50 , respectively. Moreover, while MCF7-myr-Akt cells were completely resistant to cell death when exposed to GDC-0941 (LD 0 and LD 50 >10000 nM), BKM120 treatment still led to efficient cell killing (LD 0 = 1535 ± 157 nM).Similarly, the expression of myr-Akt caused a shift in sensitivity to both GDC-0941 ( Figure 2C Overall, these data suggest that in cells, BKM120 displays activities independent of PI3K inhibition at concentrations equal or higher than 2 μM.
The off-target activity of BKM120 is linked to mitosis
In order to identify additional targets of BKM120, global gene expression profiles for BKM120, GDC-0941 and for the dual mTOR/PI3K inhibitor NVP-BEZ235 (BEZ235) were established upon exposure to concentrations corresponding to different degrees of pathway inhibition (50 or 90% inhibition, as judged by reduction of pAkt levels) in the A2058 cell line 
conditions) were identified and subjected to a gene set enrichment analysis ( Figure 3B ).
Interestingly, the gene sets with highest score were found to be related to cell cycle, spindle assembly and the metaphase checkpoint. Overall, these results suggest that at high concentrations, BKM120 displays activities that might have an impact on G2/M progression.
BKM120 blocks the prometaphase to metaphase transition?
In order to test whether BKM120 could cause a mitotic block, the effects on the cell cycle were analyzed in A2058 cells using BKM120 or GDC-0941 at concentrations sufficient to cause complete pathway inhibition (10 fold the IC 50 for phospho-Akt inhibition). Treatment with GDC-0941 had no effect on the cell cycle, whereas treatment with BKM120 led to a significant increase in the G2/M population, in comparison to control untreated cells ( Figure   4A ). The increase in G2/M occurred in a dose-dependent manner, but the concentration required to achieve half of this effect (EC 50 ) was 8-fold higher than the concentration needed to reach the EC 50 on PI3K pathway inhibition (measured by pAkt levels, Sup Figure 3A) . Furthermore, treatment with either BEZ235 or GDC-0941 at concentration as high as 5 μM, had no effect on the cell cycle distribution (Sup Figure 3B) . Figure 4) . Interestingly, treatment of these cells with the microtubule destabilizer Nocodazole caused a remarkably similar phenotype. These results suggest that at high concentrations, BKM120 causes a prometaphase to metaphase arrest in a PI3K-independent manner.
U87MG cell lines (Sup
BKM120 inhibits tubulin polymerization
To test whether BKM120 might influence microtubule dynamics, potential effects on tubulin polymerization were analyzed. Cells were pre-incubated at 4°C to cause peripheral microtubule depolymerization followed by a switch back to 37°C, either in presence or absence of inhibitors, to allow re-polymerization of the microtubule network to the rim of the cells ( Figure 5A ). In contrast to GDC-0941, incubation with BKM120 or Nocodazole enhanced the loss of the microtubule network in the cell periphery, demonstrating that BKM120 exhibits microtubule destabilizing activity.
To determine whether BKM120 would directly interfere with microtubule polymerization, in vitro polymerization assays using purified tubulin were performed. As expected, the microtubule stabilizer Paclitaxel significantly increased the tubulin polymerization kinetics, whereas Nocodazole caused the opposite effects (Sup Figure 5A) . Interestingly, and in contrast to GDC-0941, BKM120 decreased the tubulin polymerization kinetics in a concentration-dependent manner ( Figure 5C ).
To further demonstrate direct binding of BKM120 to tubulin, assessment of direct interactions upon changes in relaxation of resonances was performed by NMR spectroscopy ( Figure 5D ). These effects were tubulin concentration dependent (Sup Table 1 ) and were further confirmed by waterLOGSY relaxation experiments ( Figure 5C , left panels). The tubulin/BKM120 interaction was found to be in fast exchange as observed for other tubulin ligands (23).
Furthermore, relaxation competition studies could not demonstrate binding to the colchicine site, when well described tubulin colchicine site binders were used as competitors (Sup Figure   5B ).
The microtubule destabilizing activity of BKM120 does no translate to antitumor activity in vivo.
We previously demonstrated that BKM120 was able to cause significant regressions in the mechanistic Rat1-myr-p110α in vivo model, when dosed once per day at doses of 40 mg/kg and above (T/C of -25 and -48% at 40 and 50 mg/kg, respectively) (11). To test whether at these dose levels the exposure of BKM120 would have reached concentrations to engage its off-target (tubulin binding) activity, tumors were fixed and stained for phospho-Histone H3 levels as a mitotic marker and the mitotic index (MI) was calculated. In cellular assays, a strong increase in phospho-Histone H3 levels could be observed as early as 6 h (Sup Figure   6 ). In vivo, (Rat1-myr-p110α tumor model), no MI increase was evident at the 40 mg/kg dose with T/C of 20% and 7% at 40 and 50 mg/kg, respectively, but these differences were not statistically different (p>0.05, Sup Figure 6B ). As in the Rat1-myr-p110α model, a similar transient and statistically significant increase in MI to 3% was observed at the 50 mg/kg dose level ( Figure 6B, left panel) . Importantly, no increase in caspase 7 cleavage was observed at the 40 and the 50 mg/kg dose levels ( Figure 6B, right panel) . Altogether, these data suggest that the exposure of BKM120 at a dose of 50 mg/kg might reach sufficient blood/tumor levels to engage the off-target activity in the first 6 hours following administration which then cause a mild and transient mitotic arrest MI (3 to 5%). In contrast to BKM120, other microtubule binding agents such as Paclitaxel cause peaks of MI which range between 10 to 25% (Milas 1996) (24) . Furthermore, BKM120 induced mitotic block seemed to be reversible as soon as the compound gets cleared as no increase of MI was observed 16h after compound administration. This reversibility was also observed in in vitro pulse-chase studies where BKM120 was washed out (Sup Figure 7) . 
the so-called colchicine domain, which mostly lies within the β-tubulin subunit (28, 29) .
Taxanes and vinca-alkaloids are both high molecular weight molecules and derivatives of natural products. In contrast, colchicine-site binders are generally small molecules (30),hence we hypothesized that BKM120 might share similar binding modalities. However, NMR competition studies did not confirm this hypothesis. Further structural studies will be needed to elucidate BKM120 binding mode to tubulin.
The pronounced spindle assembly defects in mitosis seen in vitro were not observed in vivo after multiple administrations of BKM120 at a dose of 40 mg/kg. Interestingly, at a dose of 50 mg/kg, a small and transient increase of the mitotic index was observed. These findings suggest that BKM120 displays tubulin binding and microtubule destabilizing activities only above a certain concentration / exposure threshold. Furthermore, the fast binding kinetics to tubulin as well as the intrinsic compound clearance probably results in reversibility of the mitotic effects, as no accumulation of G2/M arrested cells could be detected following chronic BKM120 administration. It therefore appears that BKM120 can cause regression in PI3K-dependent tumors when administered orally to animals bearing subcutaneous tumors without engaging the tubulin off-target activity to a sufficient level to contribute to the therapeutic effect.
It is interesting to observe that the plasma exposure in patients treated with BKM120 at the efficacious MTD (100 mg, AUC: 56 h*μM) (31), lies below the exposure necessary to transiently engage the off-target in a mouse model (AUC > 65 h*μM). These findings strongly argue that in patients, the threshold for microtubule destabilizing activity of this compound is not reached. Therefore, it is anticipated that efficacy in patients will solely stem from PI3K inhibition. Further analysis of clinical data, such as the assessment of mitotic 
markers in tumor biopsies from patients treated with BKM120 will be required to fully confirm that the compound off-target activity is not clinically relevant. GDC-0941 indicates that BKM120 is more efficacious than GDC-0941. B. The small shift to the right of the peak of BKM120 indicate that BKM120 is less potent than GDC-0941. The higher peak for BKM120 indicates again that BKM120 is killing more cell lines on overall.
Figure legends
Cell lines that are not responding to GDC-0941 and do not reach a crossing point in the dose response curve, are assigned the maximum concentration tested value (i.e. 8µM), explaining the second peak at crossing point 8µM for GDC-0941. 
